Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01989585
Title Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Navitoclax + Trametinib

Dabrafenib + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST